Company patents
Aurigene Oncology Limited
Aurigene Oncology Limited's patent strategy is heavily concentrated in core pharmaceutical development, with Pharmaceutical Preparations (71.4% of portfolio) and Heterocyclic Compounds (Pharma) (67.3%) being dominant. While these core areas saw strong growth in 2024 and 2025, with Pharmaceutical Preparations growing by 100.0% and 50.0% respectively, the significant year-over-year declines so far in 2026 across most categories, such as a 66.7% drop in both Pharmaceutical Preparations and Heterocyclic Compounds (Pharma), suggest a potential shift in filing pace or focus, though 2026 data is partial.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
49 US filings (since 2023) · 8 categories · 8 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Patents
Showing 1-3 of 3
API Solid Form Engineering